Benzinga | Apr 26, 2021 11:03AM EDT

Precipio Says Contracted Annualized Revenues From Signed Customers For HemeScreen POL Exceeded $750K

Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced that currently, the contracted annualized revenues from signed customers for its HemeScreen POL (Physician Office Laboratory) testing system exceed $750,000 and for the reasons set forth below, by Q4-2021 this cohort is expected to result in reported quarterly revenues with an annualized run rate of $1,000,000.